What it is: A synthetic cyclic peptide that activates melanocortin receptors in the brain to increase sexual arousal, developed as a spinoff from Melanotan II research.
Research suggests: Approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women in 2019; clinical trials confirmed significant improvements in sexual desire and distress.
Best for: Sexual health and desire researchers
Key thing to know: Works centrally through brain melanocortin receptors rather than through blood flow like PDE5 inhibitors; the only approved melanocortin-based treatment for sexual dysfunction.
What is PT-141 (Bremelanotide)?
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors — MC1R, MC3R, and MC4R. It was developed from Melanotan II (a synthetic α-MSH analog) after researchers noticed pronounced sexual arousal as a side effect of Melanotan II's tanning research. PT-141 was then engineered to isolate the sexual-function effects and minimize pigmentation activity.
In 2019, bremelanotide was approved as Vyleesi, a subcutaneous autoinjector, for hypoactive sexual desire disorder (HSDD) in premenopausal women. This makes PT-141 one of very few peptides with full regulatory approval, based on multiple phase III randomized controlled trials. The approved indication is specific: acquired, generalized HSDD in premenopausal women.
Research into PT-141 for male sexual dysfunction, particularly erectile dysfunction where psychological or desire-related components are involved, has also been conducted, though this indication has not been approved and the evidence base is less developed than for HSDD in women.
How PT-141 Works
In research, the proposed mechanism has several parts.
A central mechanism: PT-141's mechanism differs fundamentally from PDE5 inhibitors like sildenafil or tadalafil. Those work peripherally, increasing nitric-oxide-mediated vasodilation; PT-141 works centrally, acting on MC4R receptors in the hypothalamus to activate dopaminergic pathways tied to sexual motivation and arousal. In short, it acts on desire at the brain level, not on the mechanics of blood flow.
MC4R activation: MC4R activation in the medial preoptic area and paraventricular nucleus of the hypothalamus works through melanocortin-oxytocin pathways, increasing dopamine release in limbic reward circuits. This is why PT-141 is described as addressing the “desire” component of sexual function — engaging motivational circuitry rather than simply enhancing physical response.
Pharmacokinetics: The half-life of bremelanotide is about 2.7 hours, with peak plasma concentration around 1 hour after injection. The window of effect typically begins within roughly 45 minutes and can last several hours.
What Does the Evidence Show?
The research evidence breaks down as follows.
Phase III trials: Two phase III randomized, double-blind, placebo-controlled trials (the RECONNECT studies) formed the basis for the approval of Vyleesi. Both showed statistically significant improvements in sexually satisfying events and reduced distress on validated scales. The evidence meets full Western regulatory standards — replication, blinded design, validated endpoints, and safety monitoring across over 1,200 women.
Earlier trials: Early-phase and smaller controlled studies found PT-141 produced penile erections and improved sexual-function scores in men with erectile dysfunction, including where PDE5 inhibitors had failed. The mechanistic rationale is sound — MC4R activation is relevant to male sexual motivation. However, no phase III trials were completed for male ED, and no approval was sought.
Male data: The male evidence base, while promising, remains at a moderate tier.
Relevant Labs to Review
These biomarkers are most relevant to evaluating the hormonal and endocrine context in which PT-141 is studied, particularly when sexual dysfunction may have an underlying hormonal component that should be addressed first.
Commonly Researched Alongside PT-141
PT-141 research has occasionally examined it alongside other compounds relevant to sexual motivation and hormonal health. These are research comparisons, not clinical combination recommendations.
Research Connections
Explore the Full Peptide Library
Browse research profiles for peptides across recovery, cognitive health, metabolic support, and longevity, all in one place.